sively studied in recent years, and drugs such as cefixime or El077 are on the market or under extended evaluation1*.
On the other hand, cephems with a homologated 3-substituent, (-CH2CH=CHCH2R), have been little known2'3). Because we were interested in their antibacterial activity, we synthesized 3-(2-butenyl)cephems of type 1 and unexpectedly found a simple process for preparing a novel 3-(l ,3-butadienyl)cephem (E)-2, which has been reported in a communication4*. In this report, we wish to present the chemistry concerning 1 and 2 as well as their antibacterial activity.
Oral absorption data for 3-(l,3-butadienyl)-and 3-(4-hydroxy-2-butenyl)cephems are also given. Chemistry Synthesis of the key intermediates, (E)-and (Z)-6, is portrayed in Scheme 1. Acylation of commercially available 3 yielded the amide 4, which reacted with Table 1 . Pyridine and 2,3-of 5, 7a, 7b, (Z)-7c and (E)-$) was performed using cyclopentenopyridine reacted with (E)-6 in the presence a stepwise procedure (trifluoroacetic acid-anisole, then of Nal to give the corresponding quaternary ammonio trifluoroacetic acid-H2O) to yield the novel cephems.
compounds (E)-7a and (E)-7b, while 2-(ethylmethylamino)acetamide afforded (£)-butadiene 8. With the Biological Activity and Discussion geometric isomer, (Z)-6, these amines yielded (Z)-7a~e The in vitro antibacterial activity of the novel cephaloand no butadienyl compound was obtained. These results sporins ((Z)-la~d, (^)-la, b, d and 2) against selected indicate that the products are contingent upon the pro-Gram-positive and Gram-negative bacteria is displayed portion of amine basicity to nucleophilicity as well as in Table 2 . For comparison, the MICsof ceftazidime the olefin geometry. Actually, the use of (E)-6 and di-(CAZ) and cefpirome (CPR) are also shown, isopropylethylamine, a hindered base, improved the yield In a series of 3- Abbreviations: S. a. 7, Staphylococcus aureus FDA209PJC-1; S. a. 2, S. aureus Smith; S. e., Streptococcus epidermidis IID866; S. p., S. pyogenes Cook; E. co. 1, Escherichia coli 0-1; E. co. 2, E. coli NY-17;X p., Klebsiella pneumoniae ATCC10031; E. cl., Enterobacter cloacae 963; S. m., Serratia marcescens IID620; P. r., Providencia rettgeri Y-1 ; P. a. 1, Pseudomonas aeruginosa NCTC10490; P. a. 2, P. aeruginosa ATCC8689; CPR, cefpirome; CAZ, ceftazidime.
series according to the studies done by the Taisho and Fujisawa groups7 '8) . Amongthe 3-(2-butenyl)cephems, (Z)-la was the most well-balanced, but its activity against Gram-negative bacteria was less than that of CPR. Weconsidered that this comparatively weak activity was attributed to the reduced reactivity of the /Mactam ring caused by deconjugation of the amide carbonyl with the side chain double bond. Therefore, we expected a better activity of 3-(l,3-butadienyl)cephem 2, but its activity was almost equal to that of CAZagainst Gram-positive bacteria and inferior to those of CPR and CAZagainst Gramnegative bacteria. These results suggest that steric bulkiness or spatial orientation of the substituent is another contributory factor in the antibacterial activity of these cephems.
Compounds ((£>2, (£> and (Z)-ld) were poorly absorbed by the oral route in rats. The absorbability of (£>2, (E)-U and (Z)-ld in rats were 4.4%, 6.6% and 14.2%, respectively.
Comparing (E)-ld with (Z)-ld, the (Z)-isomer exhibited somewhat higher absorption.
Disappointingly, the antibacterial activity and the oral absorbability of all tested compounds were insufficient for further development. Therefore, we turned our attention to the synthesis of new derivatives using the novel butadienyl cephem, (2T)-8, as an intermediate, which will be described in subsequent articles.
